You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Optimized lactoferrin for treatment of intracerebral hemorrhage
SBC: Pharmareview Corporation Topic: NINDSDESCRIPTION provided by applicant Intracerebral hemorrhage ICH is a major public health problem with highest mortality rate of all stroke subtypes and long term disability Since there are no available FDA approved therapies for ICH it is of enormous importance to establish effective treatment for this medical condition Following ICH the deposited blood is damaging initially via compression ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of a Broad Spectrum Antiviral for Ebola and Marburg viral Infections
SBC: Omm Scientific, Inc Topic: NIAIDDESCRIPTION provided by applicant The long term goal of this project is to gain FDA approval for commercialization of a broad spectrum small molecule antiviral agent that is effective in treating Ebola virus EBOV and Marburg virus MARV These pathogens are major biothreat agents for which there are no approved therapeutic options or vaccines The developed drug will inhibit a conserved hum ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Methamphetamine vaccine for Humans
SBC: Kadvax Technologies, Inc Topic: NIDAMethamphetamine MA use disorder is a major problem for over million people world wide with no FDA approved pharmacotherapy However anti addiction drug vaccines hold promise by inducing drug specific antibodies that form antibody MA complexes in the blood which are too large to cross the blood brain barrier thus reducing the rate and quantity of MAandapos s brain entry This inhibits MAan ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Aminooxyacetic Acid Prodrugs for Colon Cancer Therapy
SBC: CBS THERAPEUTICS, INC. Topic: 102ABSTRACT Recent studies of the applicants support the role of the endogenous gaseous biological mediator hydrogen sulfide H S in colorectal cancer In specific the selective upregulation of cystathionine synthase CBS and the subsequent production of H S in colonic cancer cells serves as a pro survival factor by stimulating tumor cell bioenergetics ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Raising the Therapeutic Index of Photodynamic Therapy with Targeted Nanosyringes
SBC: NANOHYBRIDS INC Topic: 102ABSTRACT Current clinical photodynamic therapy PDT is an effective cancer treatment that is non invasive and low cost but it has yet to become a mainstream frontline treatment The clinical efficacy of PDT in solid tumors depends on significant accumulation of the photosensitizer PS at the tumor site availability of oxygen near the photosensitizer and effective dosing of the drug light c ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of PTI DX a blood based diagnostic for Alzheimer s disease
SBC: PAIN THERAPEUTICS, INC. Topic: NIAAbstract PTI is developing PTI DX a novel quantitative blood based diagnostic candidate for Alzheimerandapos s disease AD A non invasive and inexpensive AD diagnostic is sorely needed particularly one with the ability to detect early pathological changes that precede cognitive symptoms PTI DX measures the ratio of two protein fragments in plasma and is a companion diagnostic biomark ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Microparticulate mucosal vaccine for triple-negative breast cancer
SBC: KIROMIC BIOPHARMA INC Topic: 103ABSTRACT Triple negative breast cancerTNBCis a molecular subtype of breast cancer that is negative for expression of estrogen and progesterone receptors and human epidermal growth factor receptorHERClinicallyit is characterized by aggressive behaviordistinct patterns of metastasisand high rates of recurrence and mortalitySince TNBC tumor cells lack the necessary receptorsthe disease does not respo ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Screening for Novel CBS Inhibitors for Cancer Therapy
SBC: CBS THERAPEUTICS, INC. Topic: NCIDESCRIPTION (provided by applicant): Recent studies of the applicants support the role of the endogenous gaseous biological mediator hydrogen sulfide (H2S) in colorectal cancer: selective upregulation of cystathionine-b-synthase (CBS) and the subsequent production of H2S in colonic cancer cells serves as a pro-survival factor by stimulating tumor cell bioenergetics, growth, proliferation, migratio ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Protein Bound RNA Sequencing
SBC: BIOO SCIENTIFIC CORPORATION Topic: NHGRIDESCRIPTION (provided by applicant): Protein-RNA interactions make a profound contribution to the regulatory logic of post- transcriptional control of gene expression. Tools to decipher this intricate layer of molecular interactions on a global scale are coming to the forefront of molecular biology and genomics. The most wide spread methodology to examine interactions of RNA binding proteins (RBPs ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Small Molecules To Inhibit PCSK9-LDLR
SBC: Small Molecule PPI Mimics LLC Topic: NHLBIDESCRIPTION provided by applicant This proposal is to prepare small molecules that will inhibit the protein protein interaction between a protein called PCSK and the LDLR receptor This is an extremely well validated target for reduction of andquot badandquot cholesterol LDL and therefore controlling coronary artery disease Orally available small molecules are the preferred therapeutic mo ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health